LIAN News and Press, LianBio From 04/14/22

SHANGHAI, China and PRINCETON, N.J., April 14, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the formation and members of its Scientific Advisory Board (...

SHANGHAI AND PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN) announced today that its partner, ReViral Ltd., is expected to be acquired by Pfizer Inc. (NYSE: PFE). LianBio has existing collaboration agreements with both companies, including an in-licensing agreeme...

SHANGHAI and PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the appointment of Wei Wei Chen to the company’s Board of Di...

Bristol Myers Squibb (NYSE:BMY) shared new interim data from a late-stage study to indicate that its oral cardiac myosin inhibitor, mavacamten led to sustained improvements in clinically meaningful cardiovascular outcomes in patients with symptomatic obstructive hypertrophic cardiomyopathy. T...

LianBio press release (NASDAQ:LIAN): Q4 GAAP EPS of -$0.28. Cash and cash equivalents of marketable securities of $403.2M For further details see: LianBio GAAP EPS of -$0.28

Phase 3 registrational trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing Mavacamten granted breakthrough therapy designation in China for the treatment of patients with oHCM Infigratinib approved under special...

Gainers: IGM Biosciences (IGMS) +105%. China SXT Pharmaceuticals (SXTC) +73%. Clever Leaves Holdings (CLVR) +42%. MicroVision (MVIS) +31%. LianBio (LIAN) +26%. TC Biopharm (TCBP) +26%. Robinhood Markets (HOOD) +25%. Kinnate Biopharma (KNTE) +24%. Auddia (AUUD) +23%. Molecular Templates (...

Despite recent regulatory hurdles, the U.S.-listed Chinese pharmaceutical companies have made a comeback in the morning hours on Wednesday. Notable gainers include I-Mab (IMAB +17.9%), BeiGene (BGNE +20.8%), Legend Biotech (LEGN +9.3%), Zai Lab (ZLAB +30.4%), HUTCHMED < > Limited (HCM...

Gainers: Zai Lab (NASDAQ:ZLAB) +27%. 111 (NASDAQ:YI) +26%. LianBio (NASDAQ:LIAN) +22%. BeiGene BGNE +20%. Palisade Bio PALI +10%. Losers: Talis Biomedical (NASDAQ:TLIS) -42%. Incannex Healthcare (NASDAQ:IXHL) -32%. NLS Pharmaceutics NLSP&...

SHANGHAI and PRINCETON, N.J., March 10, 2022 (GLOBE NEWSWIRE) -- Following the Determination Report of the Public Company Accounting Oversight Board (“PCAOB”) issued on December 16, 2021, on March 8, 2022 the U.S. Securities and Exchange Commission (the “SEC”) re...